Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,576 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy.
Yamamoto K, Hokimoto S, Chitose T, Morita K, Ono T, Kaikita K, Tsujita K, Abe T, Deguchi M, Miyagawa H, Saruwatari J, Sumida H, Sugiyama S, Nakagawa K, Ogawa H. Yamamoto K, et al. Among authors: morita k. J Cardiol. 2011 Mar;57(2):194-201. doi: 10.1016/j.jjcc.2010.10.007. Epub 2010 Dec 17. J Cardiol. 2011. PMID: 21168310 Free article.
Impact of CYP3A5 polymorphism on platelet reactivity at percutaneous coronary intervention and after 9 months of aspirin and clopidogrel therapy in Japanese patients with coronary artery disease.
Hokimoto S, Chitose T, Mizobe M, Akasaka T, Arima Y, Kaikita K, Iwashita S, Morita K, Miyazaki H, Oniki K, Matsui K, Nakagawa K, Ogawa H. Hokimoto S, et al. Among authors: morita k. Eur J Clin Pharmacol. 2014 Jun;70(6):667-73. doi: 10.1007/s00228-014-1672-3. Epub 2014 Apr 26. Eur J Clin Pharmacol. 2014. PMID: 24763934 Clinical Trial.
Patients with both CYP2C19 loss-of-function allele and peripheral endothelial dysfunction are significantly correlated with adverse cardiovascular events following coronary stent implantation.
Tabata N, Hokimoto S, Akasaka T, Arima Y, Sakamoto K, Yamamoto E, Tsujita K, Izumiya Y, Yamamuro M, Kojima S, Kaikita K, Kumagae N, Morita K, Oniki K, Nakagawa K, Matsui K, Ogawa H. Tabata N, et al. Among authors: morita k. J Cardiol. 2016 Jan;67(1):104-9. doi: 10.1016/j.jjcc.2015.03.010. Epub 2015 Apr 4. J Cardiol. 2016. PMID: 25851472 Free article.
Impact of esomeprazole on platelet reactivity and clinical outcome according to CYP2C19 genotype in coronary heart disease patients during dual antiplatelet therapy.
Hokimoto S, Akasaka T, Tabata N, Arima Y, Tsujita K, Sakamoto K, Kaikita K, Morita K, Kumagae N, Yamamoto E, Oniki K, Nakagawa K, Ogawa H. Hokimoto S, et al. Among authors: morita k. Thromb Res. 2015 Jun;135(6):1081-6. doi: 10.1016/j.thromres.2015.03.033. Epub 2015 Apr 11. Thromb Res. 2015. PMID: 25891840
Sex differences in the impact of CYP2C19 polymorphisms and low-grade inflammation on coronary microvascular disorder.
Akasaka T, Hokimoto S, Sueta D, Tabata N, Sakamoto K, Yamamoto E, Yamamuro M, Tsujita K, Kojima S, Kaikita K, Kajiwara A, Morita K, Oniki K, Saruwatari J, Nakagawa K, Ogata Y, Ogawa H. Akasaka T, et al. Among authors: morita k. Am J Physiol Heart Circ Physiol. 2016 Jun 1;310(11):H1494-500. doi: 10.1152/ajpheart.00911.2015. Epub 2016 Mar 18. Am J Physiol Heart Circ Physiol. 2016. PMID: 26993229 Free article.
CYP2C19 variants and epoxyeicosatrienoic acids in patients with microvascular angina.
Akasaka T, Sueta D, Arima Y, Tabata N, Takashio S, Izumiya Y, Yamamoto E, Tsujita K, Kojima S, Kaikita K, Kajiwara A, Morita K, Oniki K, Saruwatari J, Nakagawa K, Hokimoto S. Akasaka T, et al. Among authors: morita k. Int J Cardiol Heart Vasc. 2017 Apr 12;15:15-20. doi: 10.1016/j.ijcha.2017.03.001. eCollection 2017 Jun. Int J Cardiol Heart Vasc. 2017. PMID: 28616567 Free PMC article.
3,576 results